Samsung completed the investment of $110 million into GRAIL, a US biotech company that uses AI for early cancer detection through a simple blood test.

The investment, completed jointly by Samsung C&T and Samsung Electronics, gives you a clear picture of where the Korean tech giant sees its future.

GRAIL’s flagship product is Galleri, a screening service that can identify over 50 types of cancer from a single blood draw by analyzing DNA fragments for genomic signals.

GRAIL and Samsung C&T Corporation intend to collaborate to commercialize the Galleri multi-cancer early detection test in South Korea, with the potential to expand into additional Asian markets, including Japan and Singapore.

The test is already in large-scale clinical trials with the UK’s National Health Service and is on track to file for FDA approval this year. Samsung C&T secured exclusive distribution rights for Galleri in South Korea.

“This investment from the Samsung entities further strengthens our balance sheet and extends our cash runway as we advance key priorities, including securing regulatory approval and reimbursement for Galleri in the US and expanding access to multi-cancer early detection internationally,” said Aaron Freidin, Chief Financial Officer of GRAIL.

For Samsung specifically, GRAIL fits neatly into its “Connected Care” vision the idea that Galaxy Watches, the Samsung Health app, and diagnostic tools eventually form a cohesive health management ecosystem.

Samsung Electronics recently invested in Element Biosciences, a DNA sequencing firm, and acquired digital health company Zellsh.

The post Samsung invests $110 million in AI-powered cancer detection appeared first on Sammy Fans.